Avutometinib + Defactinib Combination Advancing in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) Based on Positive Data from Planned Interim Analysis of Part A of RAMP 201 Trial February 8, 2023
Positive Data and Regulatory Update from Planned Interim Analysis of Ph 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer Announced February 1, 2023
Sonnet BioTherapeutics Announces a Collaboration with Roche for the Clinical Evaluation of SON-1010 with atezolizumab in Ovarian Cancer January 17, 2023
Results from Ph 1 dose-expansion study of STRO-002 (luvelta) in patients with advanced ovarian cancer announced January 17, 2023
Enrollment Completed in the Global Registrational Ph 3 AXLerate-OC Trial for Platinum-Resistant Ovarian Cancer January 11, 2023
First Patient Dosed in Ph 2 PRESERVE-004 Trial of ONC-392 + KEYTRUDA in Patients with Platinum-Resistant Ovarian Cancer January 11, 2023
Durable Responses of Botensilimab/Balstilimab Combination in Nine Different Treatment-Resistant Cancers announced November 23, 2022
FDA restricted 2L maintenance indication for Zejula (niraparib) to only the patient population with deleterious or suspected deleterious gBRCAmut November 23, 2022
FDA grants Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer November 23, 2022
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline November 16, 2022
Retrospective Analysis of Extended Treatment Benefit from Multiple Trials of Mirvetuximab Soravtansine in Ovarian Cancer presented November 2, 2022
First US Patient Dosed in TILT-123 Immunotherapy Ph 1 Clinical Trial in Ovarian Cancer October 19, 2022
Ph 2 Trial of DNA-Damaging Agent PLX038 initiated in patients with Platinum-Resistant Ovarian Cancer October 12, 2022
Gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Responses in Ovarian Cancer and Mesothelioma October 5, 2022
Pivotal Ph 3 Trial of Olvi-Vec for the treatment of Platinum-Resistant/Refractory Ovarian Cancer initiated September 28, 2022
Enrollment of the Ph 1/2 OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer completed September 28, 2022
Applications Submitted For Rubraca® Label Expansion In The US And EU As 1L Maintenance Treatment In Advanced Ovarian Cancer Patients September 28, 2022
Oncologic Drugs Advisory Committee to review Zejula overall survival data from the NOVA Ph 3 trial in recurrent ovarian cancer September 28, 2022
Lynparza approved in China as 1L maintenance treatment with bevacizumab for HRD+ve advanced ovarian cancer September 28, 2022
Long-term data from the Ph 3 PRIMA study showed Zejula (niraparib) maintaining a sustained and clinically meaningful PFS benefit in 1L ovarian cancer patients September 13, 2022
Lynparza +/- bevacizumab demonstrates clinically meaningful survival benefit in 1L advanced ovarian cancer across PAOLA-1 and SOLO-1 Ph 3 trials September 13, 2022
Patient-Reported Outcomes with Mirvetuximab vs Chemo in FORWARD I Study Reinforces Differentiated Tolerability Profile September 13, 2022
Rubraca® (Rucaparib) As 1L Maintenance Treatment Improves PFS In Women With Advanced Ovarian Cancer Across Disease Risk Subgroups September 13, 2022
